IDNA ETF — iShares Genomics Immunology and Healthcare ETF

iShares Genomics Immunology and Healthcare ETF (IDNA)

Updated October 16, 2026.

IDNA is an ETF. its distribution rate is 0.62%, its trailing-12-month yield is 0.69%, its expense ratio is 0.47%. Dividend Vision Distribution Safety Score™ is 69/100 (Generally safe). Total return is 72.7% over the past 7.3 years, 121.4 points behind SPY at 194.1%.

iShares Genomics Immunology and Healthcare ETF is an equity fund that tracks an index of developed and emerging market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering. The fund carries a modest distribution rate with semi-annual distributions and has an expense ratio of 0.47%. It appeals to investors seeking thematic exposure to healthcare innovation and genomic advances rather than traditional dividend-focused income.

IDNA performance versus SPY

Price and return data through 2026-10-16.

Total return is 72.7% over the past 7.3 years, 121.4 points behind SPY at 194.1%. Over the past year its total return — price change plus distributions reinvested — is 65.2%. Its deepest 1-year drawdown was 10.7%.

IDNA key facts

Distribution Safety Score™

69 · Generally safe

Safety-Adjusted Yield

0.43%

Issuer

iShares

Asset type

ETF

Asset class

Equity

Inception date

06/11/2019

Expense ratio

0.47%

Distribution rate

0.62%

Distribution frequency

Semi-Annual

Trailing yield

0.69%

Last close

$40.54 (as of 2026-10-16)

AUM

$317,287,374

Average volume

204108.0

Dividend

$0.125

Ex-dividend date

06/15/2026

Payment date

06/18/2026

Beta

1.01

How Dividend Vision calculates yield and returns

Distribution rate (0.62%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (0.69%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: iShares; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IDNA risks and drawbacks

IDNA's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are semi-annual, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 10.7%.

Who may consider IDNA — and who may not

It is a weaker fit for investors who need monthly cash flow (IDNA pays semi-annual); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IDNA

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions

More securities from iShares.